Screener / SEC EDGAR /CIK 0001237831 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Globus Medical Inc GMED

Compare with peers Embed
CEO pay, fiscal year to Dec 31, 2025

Daniel Scavilla, Keith Pfeil was paid $9.7M as reported, -$742K at the share price

Proxy (DEF 14A)
CEO pay, as reported $9.7M salary, bonus and awards at grant value
CEO pay, actually paid -$742K awards valued at the share price
$100 in the shares became $134 peer group: $127
CEO pay, 5 years $32.8M up 91% while net income rose 260%

Did pay move with results?

Each line is 100 in 2021 · pay versus performance table, proxy (DEF 14A)

0100200300 20212022202320242025 CEO pay, 2021: 100CEO pay, 2022: -4CEO pay, 2023: 24CEO pay, 2024: 123CEO pay, 2025: -10 CEO pay -10 Net income, 2021: 100Net income, 2022: 127Net income, 2023: 82Net income, 2024: 69Net income, 2025: 361 Net income 361 $100 invested, 2021: 100$100 invested, 2022: 103$100 invested, 2023: 74$100 invested, 2024: 114$100 invested, 2025: 121 $100 invested 121

When the pay line climbs faster than net income and the $100 line, pay rose more than results did; when it falls with them, it followed them. "Actually paid" re-values stock awards at the share price, so it moves with the stock. Numbers as the company tagged them in its proxy.

Pay against results, year by year

Pay versus performance · proxy, filed Apr 24, 2026

Fiscal year toCEOCEO pay (reported) CEO pay (actually paid) $100 became
Dec 31, 2025Daniel Scavilla, Keith Pfeil $9.7M-$742K $134
Dec 31, 2024Daniel Scavilla $4.9M$9.5M $127
Dec 31, 2023Daniel Scavilla $4.6M$1.9M $82
Dec 31, 2022David Demski, Daniel Scavilla $8.6M-$293K $114
Dec 31, 2021David Demski $5.1M$7.7M $111

Pay versus performance table of the proxy statement (DEF 14A) filed Apr 24, 2026, as tagged by the company in XBRL. Open the proxy

Pay against free cash flow per share, at peers

Change over the years each proxy covers · pay versus performance table, DEF 14A, and 10-K XBRL

CEO pay, as reported Free cash flow per share » runs past the edge. Pay is salary, bonus and awards at grant value. FCF per share is cash from operations less capital spending, over diluted shares, from the 10-K of the same fiscal year.

GMED: CEO pay rose 91% from FY2021 to FY2025 ($5.1M to $9.7M), while free cash flow per share rose 103% ($2.12 to $4.30). Open the proxy

Sources

The pay versus performance table of the latest proxy statement, as the company tagged it in XBRL.

Also

Cash & buybacks: what the company did with its cash in the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GMED/export.csv") into a cell.

Next:Crypto holdings
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.